Development of allele-specific gene-silencing siRNAs for TGFBI Arg124Cys in lattice corneal dystrophy type i

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 2, 2014, Pages 977-985

  Courtney, David G ^a   Atkinson, Sarah D ^a,b   Moore, Johnny E ^a   Maurizi, Eleonora ^c   Serafini, Chiara ^c   Pellegrini, Graziella ^c   Black, Graeme C ^d,e   Manson, Forbes D ^d,e,f   Yam, Gary H F ^g   MacEwen, Caroline J ^b   Allen, Edwin H A ^a,b   Irwin McLean, W H ^b   Tara Moore, C B ^a,b  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e ST MARY S HOSPITAL   (United Kingdom)

^f Cathedral Eye Clinic   (United Kingdom)

^g SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

Author keywords

Allele discrimination; Lattice corneal dystrophy; RNA interference; siRNA; TGFBI

Indexed keywords

SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA;

ALLELE; ALLELIC IMBALANCE; ARTICLE; CONTROLLED STUDY; CORNEA DYSTROPHY; CORNEA EPITHELIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYROSEQUENCING; RNA INTERFERENCE; RNA SEQUENCE; WESTERN BLOTTING;

ALLELE DISCRIMINATION; LATTICE CORNEAL DYSTROPHY; RNA INTERFERENCE; SIRNA; TGFBI;

ALLELES; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CORNEAL DYSTROPHIES, HEREDITARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; GENE SILENCING; HUMANS; POINT MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SEQUENCE ANALYSIS, DNA; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84894086032     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13279     Document Type: Article

References (36)

1. Davidson BL, McCray PB. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011;12:329-340.
2. Allen EHA, Atkinson SD, Liao H, et al. Allele-specific siRNA silencing for the common keratin 12 founder mutation in Meesmann epithelial corneal dystrophy. Invest Ophthalmol Vis Sci. 2013;54:494-502.
3. Atkinson SD, McGilligan VE, Liao H, et al. Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex. J Invest Dermatol. 2011;131: 2079-2086.
4. Liao H, Irvine AD, Macewen CJ, et al. Development of allelespecific therapeutic siRNA in Meesmann epithelial corneal dystrophy. PLoS One. 2011;6:e28582.
5. Pedrioli DML, Fu DJ, Gonzalez-Gonzalez E, et al. Generic and personalized RNAi-based therapeutics for a dominant-negative epidermal fragility disorder. Invest Dermatol. 2012;132:1627-1635.
6. Munier FL, Frueh BE, Othenin-Girard P, et al. BIGH3 mutation spectrum in corneal dystrophies. Invest Ophthalmol Vis Sci. 2002;43:949-954.
7. Liu Z, Wang Y, Gong Q, Xie L. An R124C mutation in TGFBI caused lattice corneal dystrophy type I with a variable phenotype in three Chinese families. Mol Vis. 2008;14:1234-1239.
8. Munier FL, Korvatska E, Djemaï A, et al. Kerato-epithelin mutations in four 5q31-linked corneal dystrophies. Nat Genet. 1997;15:247-251.
9. Klintworth GK. Lattice corneal dystrophy. An inherited variety of amyloidosis restricted to the cornea. Am J Pathol. 1967;50: 371-399.
10. El-Ashry MF, Abd El-Aziz MM, Ficker LA, Hardcastle AJ, Bhattacharya SS, Ebenezer ND. BIGH3 mutation in a Bangladeshi family with a variable phenotype of LCDI. Eye (Lond). 2004;18:723-728.
11. Yoshida S, Yoshida A, Nakao S, et al. Lattice corneal dystrophy type I without typical lattice lines: role of mutational analysis. Am J Ophthalmol. 2004;137:586-588.
12. Dinh R, Rapuano CJ, Cohen EJ, Laibson PR. Recurrence of corneal dystrophy after excimer laser phototherapeutic keratectomy. Ophthalmology. 1999;106:1490-1497.
13. Ellies P, Renard G, Valleix S, Boelle PY, Dighiero P. Clinical outcome of eight BIGH3-linked corneal dystrophies. Ophthalmology. 2002;109:793-797.
14. Kim T, Kim T, Kim SW, Kim EK. Comparison of corneal deposits after LASIK and PRK in eyes with granular corneal dystrophy type II. J Refract Surg. 2008;24:392-395.
15. Aldave AJ, Sonmez B, Forstot SL, Rayner SA, Yellore VS, Glasgow BJ. A clinical and histopathologic examination of accelerated TGFBIp deposition after LASIK in combined granular-lattice corneal dystrophy. Am J Ophthalmol. 2007; 143:416-419.
16. Smith FJD, Hickerson RP, Sayers JM, et al. Development of therapeutic siRNAs for pachyonychia congenita. J Invest Dermatol. 2008;128:50-58.
17. Yuan C, Zins EJ, Clark AF, Huang AJW. Suppression of keratoepithelin and myocilin by small interfering RNAs (siRNA) in vitro. Mol Vis. 2007;13:2083-2095.
18. Yellore VS, Rayner SA, Aldave AJ. TGFB1-induced extracellular expression of TGFBIp and inhibition of TGFBIp expression by RNA interference in a human corneal epithelial cell line. Invest Ophthalmol Vis Sci. 2011;52:757-763.
19. Corradini F, Venturi B, Pellegrini G, De Luca M. Methods for characterization/manipulation of human corneal stem cells and their applications in regenerative medicine. Methods Mol Biol. 2012;916:357-372.
20. Nieto-Miguel T, Calonge M, de la Mata A, et al. A comparison of stem cell-related gene expression in the progenitor-rich limbal epithelium and the differentiating central corneal epithelium. Mol Vis. 2011;17:2102-2117.
21. Yam GH, Wang K, Jhanji V, Choy KW, Baum L, Pang CP. In vitro amyloid aggregate forming ability of TGFBI mutants that cause corneal dystrophies. Invest Ophthalmol Vis Sci. 2012;53: 5890-5898.
22. Davis ME, Zuckerman JE, Choi CHJ, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464:1067-1070.
23. DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2010;107:8800-8805.
24. Müller GA, Hansen U, Xu Z, et al. Allele-specific siRNA knockdown as a personalized treatment strategy for vascular Ehlers-Danlos syndrome in human fibroblasts. FASEB J. 2012; 26:668-677.
25. Lee NS, Dohjima T, Bauer G, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol. 2002;20:500-505.
26. Yang YJ, Zhao PS, Zhang T, et al. Small interfering RNAs targeting the rabies virus nucleoprotein gene. Virus Res. 2012; 169:169-174.
27. Liu J, Pendergraff H, Narayanannair KJ, et al. RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression. Nucleic Acids Res. 2013;41:8788-8801.
28. Ye L, Zhao X, Lu J, Qian G, Zheng JC, Ge S. Knockdown of TIGAR by RNA interference induces apoptosis and autophagy in HepG2 hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2013;437:300-306.
29. Braicu C, Pileczki V, Irimie A, Berindan-Neagoe I. p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells. Mol Cell Biochem. 2013;381:61-68.
30. Irvine AD, Corden LD, Swensson O, et al. Mutations in corneaspecific keratin K3 or K12 genes cause Meesmann's corneal dystrophy. Nat Genet. 1997;16:184-187.
31. Gupta SK, Hodge WG, Damji KF, Neumann PE. Lattice corneal dystrophy type 1 in a Canadian kindred is associated with the Arg124-Cys mutation in the kerato-epithelin gene. Am J Ophthalmol. 1998;125:547-549.
32. Morand S. Induction of apoptosis in human corneal and HeLa cells by mutated BIGH3. Invest Ophthalmol Vis Sci. 2003;44: 2973-2979.
33. Gu Z, Zhao P, He G, et al. An Arg124His mutation in TGFBI associated to Avellino corneal dystrophy in a Chinese pedigree. Mol Vis. 2011;17:3200-3207.
34. Escribano J, Hernando N, Ghosh S, Crabb J, Coca-Prados M. cDNA from human ocular ciliary epithelium homologous to beta ig-h3 is preferentially expressed as an extracellular protein in the corneal epithelium. J Cell Physiol. 1994;16: 511-521.
35. Takács L, Boross P, Tözser J, Módis L, Tóth G, Berta A. Transforming growth factor-beta induced protein, betaIG-H3, is present in degraded form and altered localization in lattice corneal dystrophy type I. Exp Eye Res. 1998;66:739-745.
36. Goldbard S. Bringing primary cells to mainstream drug development and drug testing. Curr Opin Drug Discov Devel. 2006;9:110-116.